Rational design of cationic lipids for siRNA delivery

Sean C. Semple(Arbutus Biopharma (Canada)), Michael J. Hope(Acuitas Therapeutics (Canada)), June Qin(Alnylam Pharmaceuticals (United States)), Lloyd B. Jeffs(Arbutus Biopharma (Canada)), Barbara L. Mui(Arbutus Biopharma (Canada)), Ismail M. Hafez(University of British Columbia), Todd Borland(Alnylam Pharmaceuticals (United States)), Rene Alvarez(Alnylam Pharmaceuticals (United States)), Masuna Srinivasulu(University of British Columbia), Kieu Lam(Arbutus Biopharma (Canada)), Antonin de Fougerolles(Alnylam Pharmaceuticals (United States)), Erin Crosley(Arbutus Biopharma (Canada)), Derrick Stebbing(Arbutus Biopharma (Canada)), Michael J Weinstein(Alnylam Pharmaceuticals (United States)), J. Robert Dorkin(Alnylam Pharmaceuticals (United States)), Pieter R. Cullis(University of British Columbia), Muthusamy Jayaraman(Alnylam Pharmaceuticals (United States)), Ed Yaworski(Arbutus Biopharma (Canada)), Ammen P. Sandhu(Arbutus Biopharma (Canada)), Ying K. Tam(Arbutus Biopharma (Canada)), Connie K Cho(Arbutus Biopharma (Canada)), Verbena Kosovrasti(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Marco A. Ciufolini(FPInnovations), Sandra K. Klimuk(Arbutus Biopharma (Canada)), Mikameh Kazem(University of British Columbia), Akin Akinc(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Lubomir V. Nechev(Alnylam Pharmaceuticals (United States)), Merete L. Eisenhardt(Arbutus Biopharma (Canada)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Jianxin Chen(Tsinghua University), Qingmin Chen(Shandong University of Political Science and Law), Ian MacLachlan(Unknown), William Cantley(Alnylam Pharmaceuticals (United States)), Soma De(Alnylam Pharmaceuticals (United States)), Kim F. Wong(University of British Columbia), Mark A. Tracy(Alnylam Pharmaceuticals (United States)), Dinah W.Y. Sah(Port Washington Public Library), Thomas D. Madden(Arbutus Biopharma (Canada)), Scott Barros(Alnylam Pharmaceuticals (United States))
Nature Biotechnology
January 17, 2010
Cited by 1,778


Related Papers